鮑斯股份(300441.SZ):截至2022年底共有研發人員300餘人
格隆匯7月24日丨有投資者向鮑斯股份(300441.SZ)提問:公司的研發團隊情況?
鮑斯股份回覆:公司注重對核心技術的培育,堅持技術創新為基石的技術發展路徑,推進新產品的研發和投入,確保公司發展後勁,增強公司核心競爭力。截至2022年底,公司共有研發人員300餘人,已有專利767項,其中發明專利48項,建有鮑斯研究院等研究中心,並和西安交大、浙江大學等國內高等院校及院所建立了良好的技術交流渠道與合作關係,成功掌握並實現了多項核心技術研發成果轉化。後續,公司將持續加大研發投入,開發新的產品,爭取在相關領域取得更好的成績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.